Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| SCCM Vision | Other Grant/Funding Number | SCCM Vision Grant |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
It is well accepted that during critical illness there is an increase in protein breakdown and loss of lean body mass. Previous studies have shown that during critical illness muscle breakdown increases dramatically. The aim of our study is to test the hypothesis that critically ill patients have improved outcomes with higher protein supplementation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Varying amounts of Beneprotein | Experimental | 1.5grams/kg/day, 2.0 grams/kg/day, and 2.5 grams/kg, day |
|
| 1 Gram - Standard Therapy given in ICU | Active Comparator | 1 gram/kg/day of protein |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Beneprotein | Dietary Supplement | The study will compare different protein supplementation amounts to determine if increased protein supplementation in critically ill patients improves outcomes. |
| Measure | Description | Time Frame |
|---|---|---|
| Cumulative Organ failure free days | The primary outcome will be cumulative organ failure free days (defined as no aggressive medical support for the patient's vital organ systems; including cardiovascular, respiratory, renal, bone marrow, and liver. | 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality | 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| Number of days in ICU | 28 days | |
| Infection Rate | 28 days | |
| Discharge location |
Inclusion Criteria:
Exclusion Criteria:
• Patients who cannot tolerate enteral nutrition
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Karen S Allen, MD | OUHSC | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| OUHSC | Oklahoma City | Oklahoma | 73104 | United States |
Not provided
| ID | Term |
|---|---|
| D016638 | Critical Illness |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 28 days |
| New or Significantly worsening skin breakdown | 28 days |
| Mechanical Vent free days | 28 days |